The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Update on Legislation, Notification Rules Concerning the Substitution of Interchangeable Biologic Drugs

Update on Legislation, Notification Rules Concerning the Substitution of Interchangeable Biologic Drugs

November 16, 2016 • By From the College

  • Tweet
  • Email
Print-Friendly Version / Save PDF
izzet ugutmen/shutterstock.com

izzet ugutmen/shutterstock.com

Although the FDA has not yet awarded the title of interchangeable to any biosimilar, legislation that governs their substitution will continue to be a dominant state issue in 2017. Since 2013, 24 states and Puerto Rico have passed legislation regarding interchangeable biologics.

You Might Also Like
  • ACR Advances Legislation to Increase Patients’ Access to Biologic Drugs to Treat Rheumatoid Arthritis and Other Conditions
  • Update on Legislation, Advocacy Efforts to Advance Rheumatology
  • Nevada Rheumatologists Take on Biologic and Biosimilar Substitution
Explore This Issue
November 2016
Also By This Author
  • ACR Delegates Move Rheumatology Concerns Forward at AMA

As many as 15 states will have biosimilar-related legislation introduced by coalitions in 2017. The ACR has been working with various coalitions across the country to ensure appropriate safeguards are put in place to protect prescriber authority and the patient–provider relationship.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Notification of Substitution

Biosimilar legislation is almost uniform across the country. If a patient is prescribed a biologic and a less expensive biologic is available that the FDA has deemed interchangeable, each state requires that the pharmacist must dispense the less expensive alternative.

Notification for prescribers has been a point of contention nationwide. Each state varies in its policy regarding prescriber notification of substitution. The national average is five business days, with exceptions being: Oregon (five calendar days), Pennsylvania (72 hours), Georgia (48 hours) and North Dakota (24 hours).1 Florida is the only state where pharmacists do not have to notify the prescriber if a substitution has been made.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

ACR policy on the notification of substitution of interchangeable biologics states that if a biologic is substituted, then the pharmacist must notify the prescriber prior to, or within 24 hours of, the substitution.2

How Rheumatologists Can Affect State Policy

Due to the frequent prescribing of biologics by rheumatologists for treatment of rheumatic disease, no other specialty has more insight to offer when it comes to these state policies. Rheumatologists who make themselves available to educate policymakers and stakeholders are a critical component of success required for a strong patient-centered notification policy.

Most legislators look to state medical societies when it comes to health policy. That is why it is incumbent on rheumatologists to become members of their state medical society and also to participate in the state society’s government affairs committee. If rheumatologists can help their state medical society develop a strong policy for prescriber notification, then the state medical society will work for this policy to be put into law at the state capital, ensuring patients are better protected when biosimilar drugs come to market.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Cauchi R. State laws and legislation related to biologic medications and substitution of biosimilars. National Conference of State Legislatures. 2016 Sep 15.
  2. Position Statement: Biosimilars. American College of Rheumatology. 2016 May 12.

Pages: 1 2 | Multi-Page

Filed Under: Biologics & Biosimilars, Drug Updates, From the College Tagged With: 2017, biologic, drug, Legislation, Medication, notification, prescriber, rheumatology, state laws, substitution, updateIssue: November 2016

You Might Also Like:
  • ACR Advances Legislation to Increase Patients’ Access to Biologic Drugs to Treat Rheumatoid Arthritis and Other Conditions
  • Update on Legislation, Advocacy Efforts to Advance Rheumatology
  • Nevada Rheumatologists Take on Biologic and Biosimilar Substitution
  • When Will Generic Biologic Drugs Become Commercially Available?

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.